New hope for tough stomach cancers: testing a Triple-Threat treatment
NCT ID NCT07334431
Summary
This study is testing a new three-drug combination for people with advanced stomach or gastroesophageal cancer that has a specific marker called HER2-positive. The main goals are to find the safest and most effective dose of the new drug fruquintinib when added to two standard cancer drugs, and to see if this combination can help control the cancer longer. It is for adults who have not yet received treatment for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University)
RECRUITINGZhengzhou, Henan, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.